Randomized Phase II Trial Evaluating the Efficacy of Paclitaxel+Bevacizumab INDUCtion Followed by at atEzolizumab+Nab-paclitaxel for PD-L1-positive Metastatic Triple Negative Breast Cancer
Latest Information Update: 03 Feb 2025
Price :
$35 *
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Paclitaxel (Primary)
- Indications Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms INDUCE Trial
- Sponsors Japan Breast Cancer Research Group
- 03 Feb 2025 New trial record